EUVIMEDOpdag EUVIMED
Crossref

Posttransplant Lymphoproliferative Disease Following Pancreas Transplantation: A 40 Year Single‐Center Experience

Abraham J Matar iD, Erik B Finger iD, Joseph Maakaron, Emmanuel Minja, Karthik Ramanathan, Vanessa Humphreville, Joseph S Rao, Jessica Fisher iD, David E R Sutherland, Arthur J Matas iD, Raja Kandaswamy

Clinical Transplantation · 2024

DOI: 10.1111/ctr.15386 ↗

At a glance

Journal article in Clinical Transplantation, 2024. Written by Abraham J Matar and 10 co-authors. Institution: Department of Surgery, Division of Transplantation, University of Minnesota, Minneapolis, Minnesota, USA. Major MEDLINE topics: Pancreas Transplantation, Lymphoproliferative Disorders, Postoperative Complications, Graft Survival. Cited 2 times so far (Crossref); 25 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Chronic immunosuppression following pancreas transplantation carries significant risk, including posttransplant lymphoproliferative disease (PTLD). We sought to define the incidence, risk factors, and long‐term outcomes of PTLD following pancreas transplantation at a single center.

Methods

All adult pancreas transplants between February 1, 1983 and December 31, 2023 at the University of Minnesota were reviewed, including pancreas transplant alone (PTA), simultaneous pancreas–kidney transplants (SPK), and pancreas after kidney transplants (PAK).

Results

Among 2353 transplants, 110 cases of PTLD were identified, with an overall incidence of 4.8%. 17.3% were diagnosed within 1 year of transplant, 32.7% were diagnosed within 5 years, and 74 (67.3%) were diagnosed after 5 years. The overall 30‐year incidence of PTLD did not differ by transplant type—7.4% for PTA, 14.2% for SPK, and 19.4% for PAK ( p = 0.3). In multivariable analyses, older age and Epstein‐Barr virus seronegativity were risk factors for PTLD, and PTLD was a risk factor for patient death. PTLD‐specific mortality was 32.7%, although recipients with PTLD had similar median posttransplant survival compared to those without PTLD (14.9 year vs. 15.6 year, p = 0.9).

Conclusions

PTLD following pancreas transplantation is associated with significant mortality. Although the incidence of PTLD has decreased over time, a high index of suspicion for PTLD following PTx should remain in EBV‐negative recipients.

Subjects

MeSH terms (MEDLINE)

Pancreas TransplantationLymphoproliferative DisordersPostoperative ComplicationsGraft SurvivalHumansMaleFemaleAdultFollow-Up StudiesRisk FactorsPrognosisMiddle AgedIncidenceSurvival RateRetrospective StudiesGraft RejectionKidney TransplantationYoung Adult

Author keywords

Epstein‐Barr virusimmunosuppressionpancreas transplantationposttransplant lymphoproliferative disease

Authors and institutions

  • Department of Surgery, Division of Transplantation, University of Minnesota, Minneapolis, Minnesota, USA.
  • Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota, USA.

ORCID profiles: Abraham J Matar, Erik B Finger, Jessica Fisher, Arthur J Matas

Cite

APA

Matar, A. J., Finger, E. B., Maakaron, J., Minja, E., Ramanathan, K., Humphreville, V., Rao, J. S., Fisher, J., Sutherland, D. E. R., Matas, A. J., & Kandaswamy, R. (2024). Posttransplant Lymphoproliferative Disease Following Pancreas Transplantation: A 40 Year Single‐Center Experience. Clinical Transplantation. https://doi.org/10.1111/ctr.15386

Vancouver

Matar AJ, Finger EB, Maakaron J, Minja E, Ramanathan K, Humphreville V, et al. Posttransplant Lymphoproliferative Disease Following Pancreas Transplantation: A 40 Year Single‐Center Experience. Clinical Transplantation. 2024. doi:10.1111/ctr.15386

BibTeX
@article{Matar2024,
  author = {Matar, Abraham J and Finger, Erik B and Maakaron, Joseph and Minja, Emmanuel and Ramanathan, Karthik and Humphreville, Vanessa and Rao, Joseph S and Fisher, Jessica and Sutherland, David E R and Matas, Arthur J and Kandaswamy, Raja},
  title = {Posttransplant Lymphoproliferative Disease Following Pancreas Transplantation: A 40 Year Single‐Center Experience},
  journal = {Clinical Transplantation},
  year = {2024},
  doi = {10.1111/ctr.15386}
}
Start for free →